There were 692 press releases posted in the last 24 hours and 169,972 in the last 365 days.

Adherium Announces Q1 Fiscal Year 2019 Investor Conference Call

/EIN News/ -- SAN MATEO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, will host a conference call on Tuesday, October 30, 2018 at 6.30pm ET to discuss first quarter fiscal year 2019 results and business update. Arik Anderson, Chief Executive Officer will host the call and will be joined by Adherium’s Chief Financial Officer, David Allinson.

Conference Call details:

Conference ID: 7995294

Dial-in Details:

Australia:  1 800 123 296 or +61 2 8038 5221
New Zealand: 0800 452 782
Hong Kong:  800 908 865
United States: 1 855 293 1544


For overseas participants, the conference call will commence at:

  • 11.30am on Wednesday, October 31, 2018      (New Zealand Standard Time)
  • 6.30am on Wednesday, October 31, 2018        (Hong Kong Time)
  • 3.30pm on Tuesday, October 30, 2018             (U.S. Pacific Daylight Time)
  • 6:30pm on Tuesday, October 30, 2018             (U.S. Eastern Daylight Time)

A recording of the call will be made available in the ‘Investor Centre’ section of the Company website at and at

About Adherium
Based in Silicon Valley, Adherium is a digital health company dedicated to the health and well-being of people with chronic conditions. The company’s pioneering end-to-end hardware and software solution is clinically proven to promote medication adherence. Adherium’s lead product is the FDA-cleared Bluetooth®-enabled Hailie™ solution for the management of respiratory conditions, which has been shown in clinical studies to reduce severe asthma attacks in adults by as much as 60 percent  and reduce hospital admission rates in children by 80 percent.  Additional applications for the company’s platform technologies are in development. Learn more at and


Global:      Vik Panda,
United States: Gilmartin Group, Leigh Salvo, 
Europe Scott Fleming,, +31 6 4687 6989
Australia:    Pegasus Corporate Advisory, Michael Brown, +61 400 248 080


Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.